Dubai, UAE – Endocare, a pioneering UAE-based metabolic health company, has announced the successful closing of a strategic financing round led by Germany’s RbetaQ Holding, to support its expansion plans across the UAE and Saudi Arabia, while strengthening its technical and operational infrastructure.
Founded by Leyla Azizova, Janik Schmalhorst, and Dr. Hecham Harb, Endocare delivers a comprehensive care model that merges evidence-based hormonal therapy with lifestyle interventions, including nutrition, exercise, sleep, and stress management — all designed to ensure sustainable weight loss and improved long-term health outcomes.
This funding milestone marks a pivotal chapter in Endocare’s journey, as it responds to growing regional demand for effective, personalised metabolic health solutions — particularly in Dubai, where a rising health-conscious population seeks sustainable approaches to weight loss.
Adding further strength to its leadership, Endocare has appointed Prof. Dr. Ashok Kaul, an expert in AI, data science, and technology, to its Board of Directors. His strategic insights are expected to fuel the development of real-world intelligent applications in patient care.
Leyla Azizova, Co-Founder and CEO, commented:
“The closing of our funding round and Dr Kaul’s appointment are pivotal milestones for Endocare. We are thrilled to accelerate our regional growth and continue delivering best-in-class care in metabolic health, weight management, and longevity science.”
Dr. Ashok Kaul added:
“Endocare’s vision aligns perfectly with my passion for using technology to elevate healthcare. I’m excited to collaborate with the team to drive meaningful impact across the region.”
Endocare is investing in tech-powered patient pathways and outcome-focused care models, reflecting its commitment to blending innovation with clinical excellence to redefine the future of metabolic healthcare.
